Yufan Huang

521 total citations
29 papers, 357 citations indexed

About

Yufan Huang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yufan Huang has authored 29 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yufan Huang's work include Child Welfare and Adoption (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Immune cells in cancer (3 papers). Yufan Huang is often cited by papers focused on Child Welfare and Adoption (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Immune cells in cancer (3 papers). Yufan Huang collaborates with scholars based in China and United States. Yufan Huang's co-authors include Zhi-Peng Peng, Wan-Ru Ning, Yan Wu, Limin Zheng, David E. Duffee, Jinhua Huang, Toni Naccarato, Xingchen Liu, Heather Larkin and Mengmeng Zhou and has published in prestigious journals such as Journal of Hepatology, Frontiers in Immunology and Journal of Ethnopharmacology.

In The Last Decade

Yufan Huang

26 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yufan Huang China 9 122 96 76 62 48 29 357
Amy J. Armstrong United States 9 48 0.4× 98 1.0× 205 2.7× 30 0.5× 32 0.7× 40 545
Yujuan Xiang China 13 38 0.3× 93 1.0× 61 0.8× 13 0.2× 59 1.2× 25 338
M J Watts United Kingdom 10 72 0.6× 141 1.5× 50 0.7× 43 0.7× 16 0.3× 14 391
Laundette P. Jones United States 9 105 0.9× 168 1.8× 152 2.0× 10 0.2× 59 1.2× 20 470
Shahzeb Hassan United States 14 29 0.2× 48 0.5× 80 1.1× 10 0.2× 63 1.3× 49 456
Frances M. Wiley United States 11 45 0.4× 51 0.5× 92 1.2× 39 0.6× 47 1.0× 13 369
Rui Xiang United States 7 9 0.1× 82 0.9× 109 1.4× 78 1.3× 27 0.6× 10 380
Susheel K. Khetarpal United States 7 21 0.2× 104 1.1× 140 1.8× 27 0.4× 70 1.5× 15 265
Deborah Richardson United Kingdom 11 57 0.5× 123 1.3× 103 1.4× 39 0.6× 17 0.4× 25 422
Chunyu Zhang China 13 55 0.5× 49 0.5× 203 2.7× 31 0.5× 85 1.8× 44 495

Countries citing papers authored by Yufan Huang

Since Specialization
Citations

This map shows the geographic impact of Yufan Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yufan Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yufan Huang more than expected).

Fields of papers citing papers by Yufan Huang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yufan Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yufan Huang. The network helps show where Yufan Huang may publish in the future.

Co-authorship network of co-authors of Yufan Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Yufan Huang. A scholar is included among the top collaborators of Yufan Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yufan Huang. Yufan Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Ke, et al.. (2025). Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma. BMC Biotechnology. 25(1). 121–121.
2.
Liu, Juntao, et al.. (2025). Polyallylamine Hydrochloride-Modified Bovine Serum Albumin Nanoparticles Loaded with α-Solanine for Chemotherapy of Pancreatic Cancer. International Journal of Nanomedicine. Volume 20. 4235–4255. 1 indexed citations
3.
Zhang, Yifan, Yilin Liu, Hanyue Xu, et al.. (2025). Adaptive Optics and Multimodal Retinal Imaging for Postoperative Evaluation in Patients With Epiretinal Membrane. Investigative Ophthalmology & Visual Science. 66(11). 22–22.
4.
Huang, Yufan, et al.. (2025). High-yield spidroin mimics for bioinspired fibers via computational design. Frontiers in Bioengineering and Biotechnology. 13. 1587546–1587546. 1 indexed citations
6.
Xu, Ziyang, Yufan Huang, Jianbin Wang, et al.. (2024). Extraction, rapid preparation and neuroprotective effect of texasin, a main active constituent from Caragana jubata (Pall.) Poir.. Natural Product Research. 39(6). 1557–1563. 1 indexed citations
7.
Huang, Yufan, et al.. (2023). Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway in vitro and in vivo. Acta Pharmaceutica. 73(1). 75–90. 5 indexed citations
8.
Lu, Tingting, et al.. (2023). The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer. Frontiers in Pharmacology. 14. 1171302–1171302. 1 indexed citations
9.
Pang, Han‐Qing, Li Xu, Jian Wang, et al.. (2023). Elucidating the chemical interaction effects of herb pair Danshen-Chuanxiong and its anti-ischemic stroke activities evaluation. Journal of Ethnopharmacology. 318(Pt B). 117058–117058. 21 indexed citations
11.
Cai, Zhongjie, et al.. (2023). Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma. Frontiers in Pharmacology. 14. 1219694–1219694. 2 indexed citations
12.
Huang, Yufan, et al.. (2023). Bone serves as a transfer station for secondary dissemination of breast cancer. Bone Research. 11(1). 21–21. 17 indexed citations
13.
Zhang, Jinrong, et al.. (2023). Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer. Frontiers in Immunology. 14. 1267322–1267322. 5 indexed citations
14.
Zhu, Wei, et al.. (2022). Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer. Frontiers in Pharmacology. 13. 1019826–1019826. 12 indexed citations
15.
Guo, Fei, et al.. (2022). Altered Molecular Pathways and Biomarkers of Endometrial Receptivity in Infertile Women with Polycystic Ovary Syndrome. Reproductive Sciences. 29(12). 3335–3345. 11 indexed citations
16.
Huang, Yufan, et al.. (2022). Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. Frontiers in Oncology. 12. 986762–986762. 8 indexed citations
17.
Peng, Zhi-Peng, Yufan Huang, Wan-Ru Ning, et al.. (2020). Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma. Journal of Hepatology. 73(4). 906–917. 99 indexed citations
18.
Lü, Huayi, et al.. (2020). A TP53-based immune prognostic model for muscle-invasive bladder cancer. Aging. 13(2). 1929–1946. 8 indexed citations
19.
Lee, Eunju, et al.. (2020). The Cumulative Effect of Prior Maltreatment on Emotional and Physical Health of Children in Informal Kinship Care. Journal of Developmental & Behavioral Pediatrics. 41(4). 299–307. 8 indexed citations
20.
Huang, Yufan, Pei Niu, & Li Huo. (2019). The Effect of Short-Term Exposure in PM0.1 on Cardiac Remodeling and Dysfunction in Myocardial Infraction Mice. Molecular & cellular biomechanics. 16(s1). 47–47.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026